Sarepta Therapeutics (SRPT) Receiving Somewhat Favorable Press Coverage, Study Finds

News headlines about Sarepta Therapeutics (NASDAQ:SRPT) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sarepta Therapeutics earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.4806199307017 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of Sarepta Therapeutics (SRPT) opened at 36.70 on Friday. The firm’s market capitalization is $2.36 billion. The company has a 50-day moving average of $37.48 and a 200 day moving average of $33.08. Sarepta Therapeutics has a 52 week low of $24.96 and a 52 week high of $63.73.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. The firm’s revenue was up 350000.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.19) earnings per share. Equities research analysts anticipate that Sarepta Therapeutics will post ($1.16) earnings per share for the current year.

A number of research firms recently issued reports on SRPT. BidaskClub cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. William Blair reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, July 27th. Morgan Stanley reiterated an “equal weight” rating and issued a $31.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, June 30th. Zacks Investment Research upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $102.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, July 12th. Eight investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $61.28.

WARNING: This piece of content was first posted by BNB Daily and is owned by of BNB Daily. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-sarepta-therapeutics-srpt-stock-price-updated-updated.html.

In related news, SVP Shamim Ruff sold 12,138 shares of the company’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $42.97, for a total transaction of $521,569.86. Following the sale, the senior vice president now directly owns 27,312 shares in the company, valued at approximately $1,173,596.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Alexander Cumbo sold 5,918 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $242,638.00. Following the sale, the senior vice president now owns 22,793 shares in the company, valued at $934,513. The disclosure for this sale can be found here. Over the last quarter, insiders sold 78,056 shares of company stock worth $3,224,208. Corporate insiders own 9.60% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply